Vitura Health (ASX: VIT) has struck a commercial distribution agreement with MedReleaf Australia which will enable the full suite of MedReleaf products to be available for the first time on Vitura’s Canview platform.
MedReleaf is a wholly owned subsidiary of Canadian-based Aurora Cannabis, which offers a wide range of pharmaceutical-grade medicinal cannabis products to the Australian market under the MedReleaf, IndiMed, Aurora, Whistler Cannabis Co, and CraftPlant brands.
The agreement will enable MedReleaf products to be listed on the Canview online ordering and management platform for alternative therapies and distributed by the Burleigh Heads Cannabis nationwide network.
Canview connects suppliers, prescribers, pharmacies, and patients through technology-driven solutions to streamline the prescribing, ordering, and management process and currently represents around 4,700 Australian pharmacies actively dispensing medicinal cannabis.
Clear Commercial Outcomes
Vitura believes the new deal has potential to contribute up to $15 million in additional annual revenue across the company’s distribution channels, subject to patient demand, product uptake, regulatory settings, and competitive dynamics.
Chief revenue officer Ryan Tattle said the strategic partnership with MedReleaf delivers clear commercial outcomes for both parties including the introduction of new products and formats over time.
“As the supplier and distribution landscape in Australia continues to rearrange and consolidate, Vitura is well-positioned to become a key distribution and sales partner for MedReleaf’s business, increasing further access for pharmacy customers and their patients,” he said.
“Our company has experienced strong revenue growth across all businesses over the last five years and we expect this new distribution agreement with MedReleaf will certainly add to that.”
Broad Business Expansion
Vitura has expanded its specialty clinics division over the past 18 months with the formation of a joint venture with Flora Holdings, which acquired the assets of the Releaf Group in late-2024.
Progress continues toward re-engagement of Releaf’s 30,000-strong patient base across five physical clinic and dispensary locations in Victoria, New South Wales and Queensland.
Mr Tattle said Releaf was now in a strong position to capitalise on the evolving regulatory landscape including telehealth and Department of Veterans’ Affairs requirements.
In early 2025, Vitura acquired online telehealth clinic Candor Medical, which provides access to an additional 15,000 active patients, and recently confirmed its integration with Vitura legacy brands Cannadoc and CDA Clinics.
